Source: Health Canada shortage reports · Updated Aug 28, 2026
Also sold as: Tyenne, Actemra, Avtozma
A shortage of Tocilizumab is anticipated but not yet confirmed. 5 product(s) have anticipated-shortage reports on file with Health Canada.
An interleukin-6 inhibitor used to treat rheumatoid arthritis and other inflammatory conditions.
Products affected
0 / 12
Reports on file
15
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Anticipated
TYENNE
400MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02552477 · Demand increase for the drug.
Anticipated
TYENNE
200MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02552469 · Demand increase for the drug.
Anticipated
TYENNE
80MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02552450 · Demand increase for the drug.
Anticipated
TYENNE
162MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02552485 · Demand increase for the drug.
Anticipated
TYENNE
162MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02552493 · Demand increase for the drug.
Resolved
AVTOZMA
200MG · SOLUTION · CELLTRION INC.
DIN 02562030 · ended Aug 18, 2026 · Demand increase for the drug.
Resolved
AVTOZMA
400MG · SOLUTION · CELLTRION INC.
DIN 02562049 · ended Aug 18, 2026 · Demand increase for the drug.
Resolved
ACTEMRA
162MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02483327 · ended Dec 6, 2022 · Demand increase for the drug.
Resolved
ACTEMRA
162MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02424770 · ended Dec 6, 2022 · Demand increase for the drug.
Avoided
ACTEMRA
80MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02350092 · ended Jun 23, 2022 · Disruption of the manufacture of the drug.
Avoided
ACTEMRA
400MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02350114 · ended Jun 22, 2022 · Disruption of the manufacture of the drug.
Avoided
ACTEMRA
200MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02350106 · ended Jun 22, 2022 · Disruption of the manufacture of the drug.
Showing 12 of 15 reports. All reports are on file with Health Canada.
What's happening
A manufacturer has told Health Canada it expects supply of Tocilizumab to fall short of demand. Anticipated shortages sometimes resolve without patients noticing; this page updates as soon as the status changes.
Tocilizumab is classified under “IMMUNOSUPPRESSANTS” (ATC L04AC).
Recent changes
Aug 28, 2026
Shortage resolved
Aug 28, 2026
Shortage resolved
Aug 21, 2026
New report filed
Aug 21, 2026
New report filed
Aug 21, 2026
New report filed
Aug 21, 2026
New report filed
Aug 21, 2026
New report filed
Common questions
What is Tocilizumab used for?
An interleukin-6 inhibitor used to treat rheumatoid arthritis and other inflammatory conditions.
When will Tocilizumab be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Tocilizumab in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.